From GlobeNewswire: 2024-03-26 16:01:00

Korro Bio, Inc. is making significant progress with its RNA editing platform, with a regulatory filing for First-in-Human study of KRRO-110 in AATD patients expected in the second half of 2024. The company achieved remarkable results, including over 50% editing in a preclinical mouse model using GalNAc conjugates in the liver.

Ending 2023 on a strong note, Korro Bio reported a balance sheet of $166 million in cash and cash equivalents, with a cash runway extending into 2026. The company is focused on developing potential disease-modifying therapies for patients and has multiple key milestones planned for 2024, including regulatory submissions and pipeline progression.

Korro Bio’s lead development candidate is KRRO-110, a potentially best-in-class therapeutic for AATD, aiming to repair an amino acid codon and restore secretion of normal AAT protein. Preclinical data showed high specificity and a durability of AAT protein increase in a preclinical human transgenic PiZ mouse model. The company also developed CHORDs for enhanced editing efficiency, with advanced OPERA platform capabilities demonstrated in NHPs.

The company’s expansion includes the addition of two independent directors to the Board and the projection of key milestones, such as a regulatory filing for KRRO-110 in the second half of 2024. With a strong financial position and continued progress in pipeline development, Korro Bio is poised for a transformative year in 2024, dedicated to providing potential therapies for patients in need.



Read more at GlobeNewswire:: Korro Reports Full Year 2023 Financial Results and